|
WO2020219718A1
|
|
Small molecule autophagy inducers for the treatment of cancer and neurodegenerative diseases
|
|
US2020325544A1
|
|
Methods for diagnosis, prognosis and treatment of primary and metastatic basal-like breast cancer and other cancer types
|
|
US2016266125A1
|
|
Methods of treating and predicting progression of cancer based on t cell subsets
|
|
US2016007896A1
|
|
Method and apparatus for in vivo surveillance of circulating biological components
|
|
CA2901737A1
|
|
Methods of diagnosing and treating cancer by detecting and manipulating microbes in tumors
|
|
WO2013173644A2
|
|
Immunological markers for adjuvant therapy in melanoma
|
|
WO2013120092A1
|
|
Methods for predicting response to cancer therapy
|
|
AU2012201082A1
|
|
Detection of Cancer Cells in Body Fluids
|
|
AU2012200624A1
|
|
Treatment of cancer and compositions
|
|
EP2670436A2
|
|
Foxc1 antibodies and methods of their use
|
|
EP2486149A1
|
|
Diagnosis of primary and metastatic basal-like breast cancer and other cancer types
|
|
AU2010215838A1
|
|
B7-H3 antibody coupled bead assay for detection of circulating tumor cells
|
|
US2010003689A1
|
|
Use of Methylation Status of MINT Loci as a Marker for Rectal Cancer
|
|
AU2009347565A1
|
|
Use of methylation status of MINT loci as marker for rectal cancer
|
|
CA2724331A1
|
|
Use of methylation status of mint loci as a marker for rectal cancer
|
|
EP2285983A1
|
|
Use of runx3 and mir-532-5p as cancer markers and therapeutic targets
|
|
US2009263812A1
|
|
Use of ID4 for diagnosis and treatment of cancer
|
|
US2009220980A1
|
|
Use of methylation status of mint loci and tumor-related genes as a marker for melanoma and breast cancer
|
|
AU2008323698A1
|
|
Utility of RET mutant in diagnosis and treatment of melanoma
|
|
CA2690879A1
|
|
Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer
|
